Hoffmann-La Roche
The study will assess the efficacy and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .
Key Inclusion Criteria: * Males or non-pregnant females aged between 18 and 75 years (inclusive) at time of signing the informed consent form (ICF). * Participants must have type 2 diabetes mellitus diagnosed at least 3 months before screening or at least 2 metabolic risk factors. * Evidence of both cirrhosis and MASH etiology, either through a historical biopsy or a biopsy at Screening. * Clinical diagnosis of cirrhosis based on the NIT algorithm. Key Exclusion Criteria: * Liver disorder other than MASH. * History or evidence of hepatic decompensation. * History or evidence of hepatocellul…
Subcutaneous injection
Subcutaneous injection